back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2025-03-19 12:14 Tx date 2025-03-17 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$300,750
+75,000 vol $4.01 each |
295,454 | |
| Filed 2024-05-15 11:27 Tx date 2024-05-13 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$295,500
+75,000 vol $3.94 each |
220,454 | |
| Filed 2023-11-27 08:52 Tx date 2023-11-08 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
38 - Redemption, retraction, cancellation, repurchase
|
-18,000 vol |
47,131 | |
| Filed 2023-08-23 12:53 Tx date 2023-08-22 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$352,500
+75,000 vol $4.70 each |
145,454 | |
| Filed 2022-12-15 15:13 Tx date 2022-12-12 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$321,250
+32,125 vol $10.00 each |
65,131 | |
| Filed 2021-12-10 14:54 Tx date 2021-12-08 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$150,060
+15,006 vol $10.00 each |
33,006 | |
| Filed 2021-12-10 14:53 Tx date 2021-12-08 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$327,660
+21,685 vol $15.11 each |
70,454 | |
| Filed 2020-11-13 14:56 Tx date 2020-11-09 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
56 - Grant of rights
|
$180,000
+18,000 vol $10.00 each |
18,000 | |
| Filed 2020-11-13 14:56 Tx date 2018-05-07 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Performance Share Units
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2020-11-13 12:47 Tx date 2020-11-09 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$233,400
+15,000 vol $15.56 each |
48,769 | |
| Filed 2019-08-30 15:16 Tx date 2019-08-30 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$6,750
+500 vol $13.50 each |
500 | |
| Filed 2019-08-30 15:16 Tx date 2018-05-07 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2019-06-11 11:00 Tx date 2019-06-07 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$189,150
+12,164 vol $15.55 each |
33,769 | |
| Filed 2018-08-23 Tx date 2018-05-07 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2018-08-23 Tx date 2018-08-22 |
$HLS
HLS Therapeutics Inc. |
Lennox, Ryan Christopher
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$180,185
+21,605 vol $8.34 each |
21,605 |